EpiCept Reports Positive Trials for Brain Tumor Compound
Posted on: Tuesday, 26 September 2006, 12:01 CDT
EpiCept has said that Myriad Genetics has conducted positive clinical trials for Azixa, a compound discovered by EpiCept and licensed to Myriad.
Azixa is being developed to treat brain cancer. Azixa represents the first confirmed clinical proof of concept for this new technology, which is the basis for the Epicept's oncology drug discovery efforts.
Based on the promising results, Myriad intends to initiate phase II clinical trials for the drug triggering a milestone payment to EpiCept.
In the phase I study of Azixa in cancer that has metastasized to the brain the drug achieved its maximum tolerated dose in patients. Myriad also noted a measured reduction in tumor size in certain patients.
"As this work proceeds, we are also advancing the lead drug candidates that have already been identified. This includes our anticipated IND filing for EPC2407, a small molecule apoptosis inducer for the treatment of certain types of cancer, later this year," remarked Jack Talley, president and CEO.
EpiCept's proprietary apoptosis screening technology can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells through the use of chemical genetics.
Source: Datamonitor
Related Articles
- Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies With REOLYSIN(R)
- EpiCept to Present Pre-Clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
- HIV Drug Shows Cancer Promise
- EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
- Chemo Drug Helps Cancer-Killing Virus
- Application of Sentinel Principle in Bladder Cancer Published in Clinical Cancer Research
- Today, There Are More Than 100 Companies Developing More Than 180 Protein Kinase Inhibitory Drugs in More Than 300 Clinical Trials Targeting Around 40 Different Cancer Indications
- Experimental Drug Stuns Cancer Doctors
- Alzheimer's Drug Fails Key Test, Myriad Says
- Technology thinks tiny to deliver drugs in cancer war ; Research in Cardiff is creating targeted designer molecules
 |
 |
User Comments (0)
RSS Feeds